Affiliations 

  • 1 School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. [email protected]
  • 2 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
  • 3 School of Applied Sciences, University of Huddersfield, Huddersfield, UK
Ir J Med Sci, 2023 Dec;192(6):2897-2904.
PMID: 36754948 DOI: 10.1007/s11845-022-03266-6

Abstract

We summarized through systematic review and meta-analysis of observational studies the risk of mortality as well as severe illness of COVID-19 caused by omicron variant relative to delta variant of SARS-CoV-2. A total of twelve studies were included. Our results showed significantly reduced odds of mortality (pooled OR = 0.33; 95% CI: 0.16-0.67) and significantly reduced odds of severe illness (pooled OR = 0.24; 95% CI: 0.21-0.28) in patients infected with the omicron variant of SARS-CoV-2 relative to their counterparts infected with the delta variant. Findings of lower disease severity following infection with the omicron variant of SARS-CoV-2 than the delta variant are encouraging during the ongoing transition from the pandemic phase into the endemic phase of COVID-19.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications